Cancer Immunology and Immunotherapy

Cancer immunology is the study of the immune system's response to cancer. It seeks to understand how cancer cells evade the immune system, how the immune system can be activated to recognize and attack cancer cells, and how the immune system can be harnessed to develop effective cancer treatments.

Immunotherapy is a type of cancer treatment that uses the body's own immune system to fight cancer. There are several different types of immunotherapy, including checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines.

Checkpoint inhibitors work by blocking the signals that cancer cells use to evade detection by the immune system, allowing the immune system to recognize and attack cancer cells.

CAR-T cell therapy involves genetically modifying a patient's own T cells to recognize and attack cancer cells. The modified T cells are then reinfused into the patient, where they can target and destroy cancer cells.

Cancer vaccines work by stimulating the immune system to recognize and attack cancer cells. Some cancer vaccines contain cancer-specific antigens that can be recognized by the immune system, while others work by stimulating the immune system in more general ways.

Immunotherapy has shown promise in the treatment of many different types of cancer, including melanoma, lung cancer, and leukemia. However, it is not effective for all patients, and research is ongoing to improve its effectiveness and identify new targets for immunotherapy.

Market Analysis: The global market for Cancer Immunology and Immunotherapy is experiencing significant growth, with estimates varying slightly across reports based on the exact year and forecast period: in 2025, the market size is projected to be around USD 136.39 Billion to USD 144.80 Billion or even USD 168.1 Billion, while forecasts project it to reach between USD 247 Billion and USD 338.40 Billion by 2033-2034, reflecting a robust compound annual growth rate (CAGR) generally ranging from 8.9% to 11.6% or higher over the forecast periods.